Search company, investor...
Search
NovioSense company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

noviosense.com

Founded Year

2012

Stage

Unattributed VC | Alive

Total Raised

$2.1M

About NovioSense

NovioSense specializes in non-invasive glucose monitoring utilizing wireless data and power to continually monitor glucose levels in tear fluid.

NovioSense Headquarters Location

Transistorweg 5

Nijmegen, 6534 AT,

Netherlands

+31 6 28876081

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NovioSense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NovioSense is included in 5 Expert Collections, including Medical Devices.

M

Medical Devices

8,490 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,421 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Diabetes

1,750 items

D

Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,901 items

NovioSense Patents

NovioSense has filed 4 patents.

The 3 most popular patent topics include:

  • Biosensors
  • Biotechnology
  • Diabetes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/18/2012

4/28/2020

Diabetes, Insulin therapies, Blood tests, Sensors, Biosensors

Grant

Application Date

4/18/2012

Grant Date

4/28/2020

Title

Related Topics

Diabetes, Insulin therapies, Blood tests, Sensors, Biosensors

Status

Grant

Latest NovioSense News

Post-Google, what does the glucose-sensing contact lens landscape look like?

Nov 21, 2018

Dutch company NovioSense's eyelid sensor shows promise; other efforts are academic. NovioSense's artist conception of its device in use. Last week, Alphabet subsidiary Verily Life Sciences announced the end, at least for the foreseeable future, of its glucose-sensing contact lens  collaboration with Novartis. Verily CTO Brian Otis gave his thoughts in a blog post at the time, stressing the learnings the company got from the project. In a recent interview with MobiHealthNews, Novartis Global Head of Digital Development Jacob LaPorte echoed those sentiments. "Novartis has elected to take a leadership position in the community. We’ve been very vocal about this and we want to drive this forward with the rest of the community. But in taking a leadership position, there are some things you’re going to have to experiment with. And like all science, not all experiments are going to pay out the way you intended," he said. While he still hopes the project could be brought back in the far future, for Novartis it stopped looking like it would be a way to help real patients any time soon — so they pulled the plug. "The way you should look at the decisions we’re making is we always want to be judicious about where we’re making investments, so that we’re confident that the investments that we’re making are going to pay the highest return on human health in a positive way," he said. "To specifically address the Verily Life Sciences project, I think that was an ambitious project where we learned a lot from doing that. There was a decision made that that may not be the best focus right now, based on the learnings that we’ve had, to actually bring something forward to impact human health, and we have to constantly look at this portfolio of opportunities and rebalance." The rest of the field Verily and Novartis aren't the only ones to give up on glucose-sensing contact lenses. After the publication of our last story, MobiHealthNews reached out to Medella CEO Harry Gandhi, who said that his company quietly pivoted out of that space a year ago. "We're re-purposing the tech to something a bit more worthwhile," he said in a LinkedIn message. "Going to be coming out with an update soon." As far as we know, that doesn't leave anyone working on commercial product that is a glucose-sensing contact lens. At least two groups of researchers, both of whom published as recently as January, are working on the tech:  a team in South Korea and a joint American-Saudi Arabian team . These academic projects are worth keeping an eye on, but both seem far away from commercialization. And then there's NovioSense, a Dutch company that's pursuing tear-based glucose sensing, just without the contact lens. Instead, the company is developing a small sensor worn inside the lower eyelid. CEO Dr. Christoper Wilson reached out to MobiHealthNews after our last story to say that his company has now completed its first human trial , published with six patients . Another study, in progress, will look at 24 patients. NovioSense's device performed comparably to both the Dexcom G4 and the Abbott Freestyle Libre in the six-patient trial. So if patients don't mind eschewing the contact lens for an eyelid-worn sensor, there may be some hope of noninvasive glucose sensing coming soon after all. Tags:

NovioSense Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NovioSense Rank

  • When was NovioSense founded?

    NovioSense was founded in 2012.

  • Where is NovioSense's headquarters?

    NovioSense's headquarters is located at Transistorweg 5, Nijmegen.

  • What is NovioSense's latest funding round?

    NovioSense's latest funding round is Unattributed VC.

  • How much did NovioSense raise?

    NovioSense raised a total of $2.1M.

  • Who are the investors of NovioSense?

    Investors of NovioSense include Fraunhofer Venture, Health Innovation Fund, NovioTech and PPM Oost.

  • Who are NovioSense's competitors?

    Competitors of NovioSense include WaveForm Diabetes and 1 more.

You May Also Like

LifeScan Logo
LifeScan

LifeScan, a maker of blood glucose monitoring products, is dedicated to improving the quality of life for people with diabetes. More diabetes specialist and pharmacists recommend LifeScan systems than any other brand. Every day, more than three million people rely on LifeScan systems for simple testing and accurate results.

WaveForm Diabetes Logo
WaveForm Diabetes

WaveForm Diabetes is delivering connected diabetes solutions that empower people to live healthier lives.

P
Pacific Diabetes Technologies

Pacific Diabetes Technologies develops a hollow glucose sensor that allows insulin infusion and continuous glucose monitoring.

Integrity Applications Logo
Integrity Applications

Integrity Applications is an engineering and software services and solutions company with a nationwide presence primarily supporting the intelligence community and other civil, defense and intelligence customers with a focus on Government space and intelligence surveillance reconnaissance systems activities. IAI's headquarters is in Chantilly, Virginia. IAI also has offices in California, Hawaii, Massachusetts, Maryland, Michigan, New Mexico, Ohio and Pennsylvania. IAI employees work on customer sites nationwide.

B
Biolinq

Biolinq develops skin-applied electrochemical sensors that analyze body fluids to provide health information. The company was founded in 2012 and is based in San Diego, California.

I
Infinovo

Infinovo is a China-based medical technology company that focuses on glucose monitoring for diabetes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.